Professor Donghyun Kim of the Department of Ophthalmology at Korea University Anam Hospital demostró the therapeutic eficacia of a new inflammatory ocular disease tratamiento, RCI001, in Sjogren's syndrome.
Sjogren's syndrome is an autoimmune disease characterized by chronic inflammation of the salivary and lacrimal glands, resulting in dry mouth and ojo seco.
It primarily occurs in the elderly, and as there actualmente está no fundamental cure, only symptomatic tratamientos are used.
To treat ojo seco caused by Sjogren's syndrome, antiinflamatorio agents such as artificial tears, topical corticosteroids, cyclosporin A, and lifitegrast are used, but they have limited effectiveness or poor ocular comfort upon instillation.
En particular, steroids carry risks of elevated presión intraocular and cataracts with long-term use, while cyclosporin A and lifitegrast are known to cause burning and stinging upon instillation. Therefore, there is a need for new tratamientos with excellent antiinflamatorio effects and favorable ocular comfort.
RCI001, jointly developed by RudaCure and Hanlim Pharmaceutical, is a novel topical eye drop formulación that ha sido confirmó to have simultaneous antiinflamatorio and antioxidante activity through TRPV1 downstream signal modulation.
En este estudio, a Sjogren's syndrome model was establecido by injecting botulinum toxin into the lacrimal glands of mice, and RCI001 was administered topically for 14 days to evaluate its effects. The resultados showed significant improvement in volumen lagrimal, epitelial corneal damage, and conjunctival goblet cell density.
El profesor Kim declaró: "RCI001 demonstrates meaningful therapeutic potential not only for general enfermedad de ojo seco but also for autoimmune-related ojo seco such as Sjogren's syndrome, and further clinical desarrollo is anticipado."
